At the news
? BEARISHIMPACT 7/10 EFFECT filed Apr 1, 2026 at 00:15 ET
Solid Biosciences Inc. has two S-3 shelf registration statements that became effective on March 31, 2026, enabling the resale of up to 42.8 million shares by selling stockholders from a prior private placement, including pre-funded warrants, and 1.3 million shares held by FA212 LLC. The company will not receive proceeds from these sales, but the potential for significant near-term share issuance creates a dilution overhang.
- Two S-3 shelf registrations became effective on March 31, 2026 (File Nos. 333-294460 and 333-294456).
- First registration covers resale of up to 42,780,739 shares, including 27.8 million shares issuable upon exercise of pre-funded warrants from a March 2026 private placement.
- Second registration covers resale of 1,316,899 shares held by FA212 LLC, acquired in a January 2026 private placement.
- Solid Biosciences will not receive any proceeds from the sale of these shares by the selling stockholders.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access